Severe acute respiratory syndrome (SARS) was reported in 8447 cases with 811 deaths worldwide from February to June 2003 ([@bib24], [@bib23], [@bib5]). A novel coronavirus, SARS-coronavirus (SARS-CoV) was identified as the etiological agent of the disease ([@bib15], [@bib17], [@bib28], [@bib11]). SARS-CoV particle contains a single positive-stranded RNA genome encoding for replicase, spike, envelope, membrane, and nucleocapsid ([@bib16], [@bib6], [@bib9]). The SARS-CoV 3CL^pro^ mediates the proteolytic processing of replicase polypeptides into functional proteins, playing an important role in viral replication. Therefore, the SARS-CoV 3CL^pro^ can be considered an attractive target for developing effective drugs against SARS. Several potential 3CL^pro^ inhibitors with a 50% inhibitory concentration (IC~50~) below 10 μM were identified from the large number of the structurally diverse small molecules ([@bib13], [@bib10]).

*Isatis indigotica* root and phenolic Chinese herbs were frequently used for the prevention of SARS during the SARS outbreaks in China, Hong Kong, and Taiwan. *I. indigotica* root (*Radix isatidis*), belonging to the family Cruciferae, is native to China. Antiviral effects of *I. indigotica* root were found against influenza, hepatitis A and Japanese encephalitis ([@bib25], [@bib29]). *I. indigotica* root contains indigo, indirubin, indican (indoxyl-β-[d-]{.smallcaps}glucoside), β-sitosterol, γ-sitosterol, sinigrin, etc. ([@bib7]). Indigo and indirubin were identified as the promiscuous chymotrypsin inhibitors ([@bib20]). Recently, an anti-influenza virus effect of indirubin has been demonstrated ([@bib19]). In addition, several herb-derived phenolics aloeemodin, hesperetin, quercetin, and naringenin have been accredited with antiviral effects against poliovirus, vesicular stomatitis virus, Sindbis virus, herpes simplex virus types 1 and 2, parainfluenza virus, and vaccinia virus ([@bib26], [@bib1], [@bib22], [@bib14]).

In this study, we characterized the anti-SARS-CoV 3CL^pro^ effect of the water extract of *I. indigotica* root, *I. indigotica* root-derived compounds, and herb-derived phenolics using a cell-free cleavage and cell-based cleavage assay.

The root of *I. indigotica* was purchased from Sun Ten Pharmaceutical Corporation (Taiwan). The plant root of *Isatidis indigotica* was extracted twice with 10 volumes of distilled boiling water for 1 h. The aqueous extract was concentrated under the reduced pressure at 50 °C, passed through 0.22-μm filters for sterilization, and diluted in culture medium to make a stock concentration of 10 mg/ml. Indigo and indirubin were kindly provided by Dr. Yuan-Shiun Chang, professor for Institute of Chinese Pharmaceutical Sciences, China Medical University. Indican (indoxyl-β-[d]{.smallcaps}-glucoside), β-sitosterol, sinigrin, aloe emodin, hesperetin, quercetin, naringenin, daidzein, emodin, and chrysophanol were purchased from Sigma Chemical.

To examine the *trans*-cleavage of SARS-CoV 3CL^pro^ in the cell-free assay, recombinant 3CL^pro^ was expressed in *E. coli* and purified using the HisTrap Kit (Amersham) as described in our previous report ([@bib18]). Coomassie Blue-staining revealed that recombinant 3CL^pro^ contained a major 34-kDa band for the monomer and a minor 68-kDa band for the dimer ([Fig. 1](#fig1){ref-type="fig"}A, lane 2). The cleavage substrate (TVRLQAGNATE) was generated as the substrate fusion protein with the N-terminal S-Tag and the C-terminal HSV-Tag. In the cell-free cleavage assay, the substrate fusion protein that was captured by anti-HSV-Tag antibodies in wells incubated with soluble 3CL^pro^ for 3 h at 37 °C. The non-cleavage substrate protein was detected by an Enzyme Linked Immunosorbent Assay (ELISA) using peroxidase-conjugated S protein. ELISA showed that cell-free proteolytic activity correlated, in concentration-dependent manner, with the serial twofold dilution of recombinant 3CL^pro^ protein in the range from 15 μg/ml to 240 μg/ml ([Fig. 1](#fig1){ref-type="fig"}B). Subsequently, the anti-3CL^pro^ effect by the extract of *I. indigotica* root was evaluated using the cell-free cleavage assay. The cell-free cleavage assay indicated that the extract of *I. indigotica* root had a dose-dependent anti-3CL^pro^ effect with an IC~50~ of 53.8 ± 4.2 μg/ml ([Fig. 2](#fig2){ref-type="fig"} ; [Table 1](#tbl1){ref-type="table"} ).Fig. 1Cell-free cleavage activity of recombinant SARS-CoV 3CL^pro^. (A) The purified 3CL^pro^ recombinant protein at the 1 mg/ml was analyzed by 10% SDS--PAGE with Coomassie blue staining (lane 2). (B) The *trans*-cleavage of the 3CL^pro^ with a substrate fusion protein was determined using the ELISA. The substrate fusion protein was captured with anti-HSV mAb, followed by incubation with the serial dilution of the 3CL^pro^. The non-cleavage of the fusion protein was detected using the S protein-HRP conjugate and ABTS/H~2~O~2~ substrates. The ELISA product was measured at A405 nm. The relative cell-free cleavage activity was calculated as $1 - (\text{A}405_{3\text{C}\text{L}^{\text{pro}}})/(\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}})$.Fig. 2Inhibition of the cell-free cleavage of the 3CL^pro^ by the *Isatis indigotica* root extract. The extract of the *I. indigotica* root was added into the mixture of the substrate fusion protein and the 3CL^pro^, and then incubated at room temperature for 3 h. The non-cleavage of substrate fusion protein was detected using the S protein-HRP conjugate and ABTS/H~2~O~2~ substrates. The ELISA product was measured at A405 nm. The relative inhibition of cell-free cleavage activity was calculated as $1 - (\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}} - \text{A}405_{3\text{C}\text{L}^{\text{pro}}\,\text{with}\,\text{inhibitor}})/(\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}} - \text{A}405_{3\text{C}\text{L}^{\text{pro}}})$.Table 1The inhibitory effect on cell-free and cell-based cleavage activity of the SARS-CoV 3CL^pro^CompoundStructureIC~50~[a](#tbl1fn1){ref-type="table-fn"} of cell-free cleavage (μg/ml)IC~50~[a](#tbl1fn1){ref-type="table-fn"} of cell-based cleavage (μg/ml)CC~50~[b](#tbl1fn2){ref-type="table-fn"} of cell death (μg/ml)*Isatis indigotica* root53.8 ± 4.2191.6 ± 8.2\>5000Indigo![](fx1.gif)37.3 ± 8.1 (300 μM)190 ± 2.6 (752 μM)917 ± 18 (7375 μM)Indirubin![](fx2.gif)81.3 ± 5.2 (293 μM)NS[c](#tbl1fn3){ref-type="table-fn"}Indican![](fx3.gif)33.1 ± 1.2 (112 μM)NS[c](#tbl1fn3){ref-type="table-fn"}Sinigrin![](fx4.gif)50.3 ± 1.5 (121 μM)90.1 ± 4.2 (217 μM)\>5000 (\>10,000 μM)Beta-sitosterol![](fx5.gif)47.8 ± 8.6 (115 μM)502.1 ± 2.9 (1210 μM)613 ± 9 (1475 μM)Aloeemodin![](fx6.gif)35.7 ± 1.5 (132 μM)99.1 ± 2.1 (366 μM)3135 ± 9 (11,592 μM)Hesperetin![](fx7.gif)18.1 ± 0.6 (60 μM)2.5 ± 0.8 (8.3 μM)820 ± 15 (2718 μM)Daidzein![](fx8.gif)26.8 ± 1.2 (105 μM)NS[c](#tbl1fn3){ref-type="table-fn"}[^1][^2][^3]

The cell-based cleavage assay of 3CL^pro^ for screening inhibitors does not require purification of the active 3CL^pro^, and represents closely the natural physiological state. Therefore, we used the cell-based cleavage assay for examining the inhibitory efficacy of the 3CL^pro^ inhibitors. For the cell-based cleavage assay, the in-frame construction of the 3CL^pro^, the substrate, and the luciferase, designed as the plasmid pcDNA3.1-3CL^pro^-S-Luc, was co-transfected with the indicated vector pEGFP-N1 into Vero cells. The stable cell clone for the expression of the 3CL^pro^--substrate--luciferase fusion protein was selected by Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% FBS and 800 μg/ml of neomycin G418 ([Fig. 3](#fig3){ref-type="fig"}A). Since a more than 30 kDa protein fused at the N-terminus of the luciferase resulted in a dramatic decrease of luciferase activity ([@bib12]), the detection of luciferase activity could be considered as a measure for the *cis*-cleavage by the SARS-CoV 3CL^pro^. Western blotting with the anti-luciferase monoclonal antibody showed a 94-kDa band for the fusion protein 3CL^pro^-S-Luc and a 60-kDa band for the luciferase in Vero cells transfected with the plasmid pcDNA3.1-3CL^pro^-S-Luc (data not shown). The relative luciferase activity in the transfected cells was subsequently measured using the dual Luciferase Reporter Assay System ([Fig. 3](#fig3){ref-type="fig"}B). In the cell-based cleavage assay, the extract of *I. indigotica* root significantly inhibited the *cis*-cleavage activity of the SARS-CoV 3CL^pro^ with an IC~50~ of 191.6 ± 8.2 μg/ml ([Fig. 4](#fig4){ref-type="fig"} ; [Table 1](#tbl1){ref-type="table"}). The IC~50~ value from cell-based assay by the *I. indigotica* root extract was twofold higher than the IC~50~ value from the cell-free assay. The reason may be that the *I. indigotica* root extract could contain some inhibitory compounds that cannot permeate cellular membranes to reach intracellular SARS-CoV 3CL^pro^. The results of cell-free and cell-based cleavage assays demonstrated that the *I. indigotica* root extract might contain potent anti-SARS-CoV 3CL^pro^ compounds.Fig. 3Cell-based cleavage assay of the 3CL^pro^ in Vero cells. (A) Vero cells were transfected with the plasmid containing the 3CL^pro^--substrate--luciferase in-frame gene plus the indicated vector pEGFP-N1. (B) Relative Luc activity in the dilution of transfected cell lysates was determined using the dual Luciferase Reporter Assay System and the Luminometer TROPIX TR-717.Fig. 4Inhibition of the cell-based cleavage of the 3CL^pro^ by the *Isatis indigotica* root extract. Vero cells generating the 3CL^pro^--substrate--luciferase fusion protein were treated with the indicated concentration of the *I. indigotica* root extract. Equal amounts (100 μg) of cell lysates were used to determine the luciferase activity (LUC) using the dual Luciferase Reporter Assay System. The relative inhibition of cell-based cleavage activity was calculated as 1 − (LUC~with\ inhibitor~)/(LUC~without\ inhibitor~).

The in vitro cytotoxicity profile of the *I. indigotica* root extract was examined using Vero cells. Vero cells in MEM medium with 10% FBS were plated in 96-well plates (5 × 10^4^  cells/well) and then treated with the indicated compounds. After the treatment for 20 h, 25 μl of a MTT solution at 5 mg/ml was added to each well and incubated at 37 °C in 5% CO~2~ for 3 h. After a three-time washing of phosphate buffer saline, 100 μl DMSO was then added into the plates for dissolving the formazan crystals. OD~570--630~ in each well was then measured with a micro-ELISA reader. The result indicated that the 50% cytotoxic concentration (CC~50~) was greater than 5000 μg/ml.

Five major compounds of the *I. indigotica* root, including indigo, indirubin, indican, sinigrin, and beta-sitosterol were further tested for anti-SARS-CoV 3CL^pro^ action ([Fig. 5](#fig5){ref-type="fig"} , [Table 1](#tbl1){ref-type="table"}). Of the five compounds, sinigrin, beta-sitosterol and indigo dose-dependently inhibited cleavage activities of the 3CL^pro^ in cell-free and cell-based assays ([Fig. 5](#fig5){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). The IC~50~ in the cell-free assays was 115 μM for beta-sitosterol, 121 μM for sinigrin, and 300 μM for indigo. The cell-based assay indicated that sinigrin (IC~50~: 217 μM) was more efficient in blocking the cleavage processing of the 3CL^pro^ than indigo (IC~50~: 752 μM) and beta-sitosterol (IC~50~: 1210 μM). Sinigrin showed a strong correlation between the effects on cell-free and cell-based cleavage of the SARS-CoV 3CL^pro^. Moreover, indigo (CC~50~: 7.4 mM) and sinigrin (CC~50~: \>10 mM) were not toxic to Vero cells. Sinigrin, an antioxidant, has been reported to possess inhibitory effects on quinine reductase and glutathione S-transferase, antiproliferative effects against cancer cells, and antimicrobial activity against *Bacillus subtilis* and *Saccharomyces cerevisiae* ([@bib2], [@bib21], [@bib27]). This study is the first report in that sinigrin significantly blocks the cleavage processing of a viral protease.Fig. 5Inhibition of the cell-free cleavage of the 3CL^pro^ by the compounds derived from *Isatis indigotica* root. The indicated compound was added into the mixture of the substrate fusion protein and the 3CL^pro^, and then the uncleaved substrate was detected using the S protein-HRP conjugate and ABTS/H~2~O~2~ substrates. The ELISA product was measured at A405 nm. The relative inhibition of cell-free cleavage activity was calculated as $1 - (\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}} - \text{A}405_{3\text{C}\text{L}^{\text{pro}}\,\text{with}\,\text{inhibitor}})/(\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}} - \text{A}405_{3\text{C}\text{L}^{\text{pro}}})$.

Seven phenolic compounds, aloeemodin, hesperetin, quercetin, naringenin, daidzein, emodin, and chrysophanol were also tested for their inhibitory effects on the SARS-CoV 3CL^pro^ ([Fig. 6](#fig6){ref-type="fig"} ; [Table 1](#tbl1){ref-type="table"}). Only two of the phenolic compounds, aloeemodin and hesperetin dose-dependently inhibited cleavage activity of the 3CL^pro^ in cell-free and cell-based assays ([Fig. 6](#fig6){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). In the cell-free assay, the IC~50~ values were 132 μM for aloe emodin and 60 μM for hesperetin. Quercetin has been reported to block the entry of SARS-CoV into host cells ([@bib31]). However, no inhibitory effect on SARS-CoV 3CL^pro^ was found for quercetin in the cell-free and cell-based cleavage assays. Interestingly, hesperetin (CC~50~: 2.7 mM) had an IC~50~ of 8.3 μM in the cell-based assay ([Table 1](#tbl1){ref-type="table"}). Hesperetin is poorly soluble in water; so, hesperetin was less inhibitory in the cell-free assay than in the cell-based assay. The finding of the anti-3CL^pro^ effects of hesperetin at the micromolar range was consistent with a previous report indicating that hesperetin had an inhibitory activity on Sindbis virus infection with an IC~50~ of 20.5 μg/ml (about 68 μM) by plaque assay ([@bib22]). Of the compounds tested, hesperetin was the most potent inhibitor of SARS-CoV 3CL^pro^ ([Table 1](#tbl1){ref-type="table"}).Fig. 6Inhibition of the cell-free cleavage of the 3CL^pro^ by the phenolic compounds. The indicated compound was added into the mixture of the substrate fusion protein and the 3CL^pro^, and then the uncleaved substrate was detected. The relative inhibition of cell-free cleavage activity was calculated as $1 - (\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}} - \text{A}405_{3\text{C}\text{L}^{\text{pro}}\,\text{with}\,\text{inhibitor}})/(\text{A}405_{\text{no}\, 3\text{C}\text{L}^{\text{pro}}} - \text{A}405_{3\text{C}\text{L}^{\text{pro}}})$.

Our results have demonstrated significantly inhibitory effects on SARS-CoV 3CL^pro^ by *I. indigotica* root extract, indigo, sinigrin, aloeemodin and hesperetin in the micromolar range. Particularly, the cell-based assay demonstrated that hesperetin (IC~50~: 8.3 μM) and sinigrin (IC~50~: 217 μM) could be potential inhibitors of SARS-CoV 3CL^pro^. In addition, sinigrin and hesperetin with a CC~50~ of over 2 mM were considerably less cytotoxic to Vero cells ([Table 1](#tbl1){ref-type="table"}). Akin to other reported anti-SARS substances, such as glycyrrhizin ([@bib3]), nelfinavir ([@bib30]), aurintricarboxylic acid ([@bib8]), and interferon ([@bib4]), the compounds reported here may be considered as potential leads in the development of inhibitors of SARS-CoV 3CL^pro^.
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[^1]: IC~50~ (50% inhibitory concentration) was the concentration requiring for 50% inhibition on the *cis*-cleavage activity of 3CL^pro^.

[^2]: CC~50~ (50% cytotoxic concentration) was the concentration giving half the OD~570--630~ of mock cells in MTT assay. IC~50~ and CC~50~ were determined using a computer program based on Fisher\'s statistical model.

[^3]: Not significant.
